S
AVIR icon

Sunpointe’s Atea Pharmaceuticals AVIR Stock Holding History

Sunpointe’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64.3K Hold
11,943
– – 0.02% 266
2025
Q4 		$42.6K Hold
11,943
– – 0.01% 261
2025
Q3 		$34.6K Hold
11,943
– – 0.01% 255
2025
Q2 		$43K Hold
11,943
– – 0.02% 235
2025
Q1 		$35.7K Hold
11,943
– – 0.02% 186
2024
Q4 		$40K Hold
11,943
– – 0.02% 194
2024
Q3 		$40K Hold
11,943
– – 0.03% 169
2024
Q2 		$39.5K Hold
11,943
– – 0.03% 163
2024
Q1 		$48.3K Hold
11,943
– – 0.05% 134
2023
Q4 		$36.4K Buy
+11,943
New +$36.2K 0.05% 131

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Sunpointe's AVIR Position: Q1 2026 in Review

Sunpointe held its Atea Pharmaceuticals (AVIR) position steady in Q1 2026 at 11,943 shares worth $64.3K. The position accounts for 0.02% of the portfolio, ranked #266.

Sunpointe first reported a position in AVIR in Q4 2023 and has held it in 10 quarters since. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Sunpointe held 11,943 shares of Atea Pharmaceuticals worth $64.3K as of Q1 2026.
  • Sunpointe left its Atea Pharmaceuticals share count unchanged in Q1 2026.
  • Atea Pharmaceuticals made up 0.02% of Sunpointe's portfolio in Q1 2026, its #266 holding.
  • Sunpointe first reported a position in Atea Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Sunpointe's 13F filing for Q1 2026, filed 21 Apr 2026.